Doxorubicin (Dox), an effective anticancer agent, is known for its genotoxic effects on normal cells. Phenolic compounds, renowned for their antitumor, antioxidant, and antigenotoxic properties, have gained prominence in recent years. This study investigates the individual and combined protective effects of rosmarinic acid (RA) and epigallocatechin gallate (EGCG) against Dox-induced genotoxicity using various in vitro test systems. The synergistic/antagonistic interaction of these combinations on Dox's chemotherapeutic effect is explored in breast cancer cell lines. Both RA and EGCG significantly mitigate Dox-induced genotoxicity in comet, micronucleus, and Ames assays. While Dox exhibits higher selectivity against MCF-7 cells, EGCG and RA show greater selectivity against MDA-MB-231 cells. The coefficient of drug interaction reveals a synergistic effect when RA or EGCG is combined with Dox in breast cancer cells. In conclusion, both EGCG and RA effectively reduce Dox-induced genetic damage and enhance Dox's cell viability-reducing effect in breast cancer cells.
Keywords: Ames test; Doxorubicin; comet assay; epigallocatechin gallate; micronucleus; rosmarinic acid.
Rosmarinic acid (RA) showed protective effect against doxorubicin-induced genotoxicity.Epigallocatechin gallate (EGCG) demonstrated pro-oxidant properties at high concentrations.EGCG and RA selectively targeted MDA-MB-231 cells.Synergistic effect was observed when EGCG or RA was administered together with Dox on breast cancer cells.